pharmaceutical daily news

Alvogen has launched its generic equivalent to Indivior UK LLC’s Suboxone sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the U.S.

Oncology drug specialist ADC Therapeutics has continued with its Phase I clinical trial of combination of ADCT-402 (loncastuximab tesirine) with Pharmacyclics LLC’s ibrutinib, by dosing patients with advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).

Beximco Pharmaceuticals Limited will buy from Novartis’ Sandoz a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the US for an undisclosed amount in cash, the company said Wednesday in a press release. Accorgint to Beximco Pharma’s announcement, its has six US FDA approved products. Four of these products

Pfizer and Eli Lilly have been testing tanezumab in patients with moderate-to-severe chronic low back pain (CLBP) in a Phase 3 study, with certain success, as tanezumab 10 mg met the primary endpoint by reducing pain at 16 weeks compared to placebo.

Roche on Tuesday got nod from the US Food and Drug Administration (FDA) that it’s anti-cancer combination might have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.

Basilea Pharmaceutica’s revenue grew of 31% for the full year, reaching CHF 133 million (€117M), the company said on Tuesday, noting it’s year-end cash position being at CHF 223 million.

Jining, Shandong Province-based Spring Pharmaceutical Group, Inc. posted net income of $4.34 million, compared to $2.78 million for the same period of the prior fiscal year.

The Superior Court of California, County of Los Angeles rejected all but one of Gilead’s arguments to dismiss the HIV/AIDS patients’ legal theories against the company’s TDF-based HIV/AIDS drug, that cause permanent damage tokidneys and bones.